Fear is in the air. Sure, the S&P 500 (^GSPC +2.91%) is holding up pretty well in the face of significant uncertainty. However, implied volatility has risen sharply in recent weeks.Should investors stay away from all stocks with a 10-foot pole? Nope. Here are three dividend stocks you can buy with no hesitation. 1. Johnson & JohnsonJohnson & Johnson (JNJ +0.83%) remains a favorite among investors who want to sleep at night without worrying about their portfolios. The healthcare giant has an AAA credit ratin ...

Investment Thesis I value Johnson & Johnson (NYSE:JNJ) with a Hold judgment. The company is well-appreciated by investors for being one of the biggest and most diversified players in the pharmaceutical industry, a defensive stock with a long history (62 years) of dividend increase. Given the considerable capital increase the company has been realizing in the last year, this analysis aims to quantitatively evaluate if the company is still undervalued, fairly valued, or overvalued. The outcome of the Monte Ca ...

Core Viewpoint - Equity markets are experiencing significant volatility, making dividend stocks an attractive investment option due to their ability to provide consistent payouts and stability during economic challenges [1] Company Overview - Johnson & Johnson (NYSE: JNJ) is highlighted as a standout dividend company, being part of the "Dividend Kings" group, which consists of companies with 50 or more consecutive annual dividend increases [2] - The company has increased its dividends for 63 consecutive years, showcasing a strong track record among its peers [2] Business Operations - Johnson & Johnson's pharmaceutical division has a diverse portfolio, including drugs in major therapeutic areas like immunology and oncology, with several products generating over $1 billion in annual sales [3] - The company is well-positioned to recover from challenges such as patent expirations, as evidenced by its response to the introduction of biosimilars for Stelara [3] Financial Performance - Johnson & Johnson projects sales to reach $100 billion this year, marking only the second instance of a biopharma company achieving this milestone, despite facing government-led price negotiations that may lower sales for some products [4] - The company has a robust pipeline that is expected to yield additional successful products over time [4] Medical Device Segment - The medical device business of Johnson & Johnson is also diversified, with recent efforts to gain approval for the Ottava robotic-assisted surgery system, targeting a promising niche in robotic surgery [5] Financial Health - Johnson & Johnson holds a AAA rating from S&P Global, indicating the highest level of financial health and stability [5]

Core Viewpoint - Johnson & Johnson stock is experiencing a rebound after a period of sideways trading, with a notable 43% increase over the past year, and is currently forming a flat base with a buy point of $251.71 [2][4]. Company Performance - Johnson & Johnson's innovative medicines division is projected to contribute 64% of total sales in the first quarter [4]. - The company is set to report its first-quarter earnings on April 14, with analysts expecting adjusted earnings of $2.68 per share on sales of $23.61 billion, indicating a sales growth of nearly 8% despite a projected earnings dip of over 3% [8][9]. Product Developments - Recent studies show that nearly 60% of adolescents with plaque psoriasis achieved clear skin after a year of treatment with the drug Icotyde, with 86% of patients experiencing a 90% reduction in psoriatic lesions [5]. - Johnson & Johnson reported that 89% of patients responded positively to an experimental treatment for bladder cancer and has submitted an application for European approval of Tecvayli for advanced multiple myeloma [6]. - The European Commission approved the prostate cancer pill Akeega, and the FDA granted Fast Track designation to nipocalimab for lupus patients [7]. Market Position - Johnson & Johnson stock has an IBD Composite Rating of 91, indicating it outperforms 91% of all stocks based on fundamental and technical measures [11]. - The stock's relative strength rating is also higher than the broader medical-diversified industry group, which has an RS Rating of 68 [12]. Sales Projections - The company's leading product, Darzalex, is expected to generate $3.85 billion in sales, growing nearly 19%, while Tremfya sales are projected to surge over 49% to $1.43 billion [9][10]. - Medical device sales are anticipated to increase by 6.5% to $8.54 billion [10].

Ariel Investments, an investment management company, released its "Ariel Focus Fund" fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. Ariel Focus Fund delivered mixed results in the fourth quarter of 2025, declining -0.50% and underperforming both the S&P 500 and Russell 1000 Value indices, which gained +2.66% and +3.81%, respectively, although the fund outperformed both benchmarks over the full year with a +20.97% return. The quarter took place in a resilient U.S. market en ...

Johnson & Johnson (NYSE:JNJ) was among the stocks Jim Cramer highlighted, along with his latest game plan as the oil-shock-driven sell-off continues. Cramer mentioned the stock during the episode and said: Now, what I suggest you do is look at Johnson & Johnson. Until it became clear that the impact wouldn’t be as bad, the stock was in free fall, and then when it was clear, it went from $140 to $230 almost in the blink of an eye. I think the same thing will happen here. Stock market data. Photo by Bura ...

Quick Read Johnson & Johnson (JNJ) raised its quarterly dividend from $1.24 to $1.30 per share (5% increase) and extended its consecutive dividend hike streak to 63 years, yielding 2.14% annually with a sustainable 46.7% payout ratio and $19.7 billion in free cash flow. Pfizer (PFE) carries payout ratio risk at 118.6% despite higher yield, while Merck (MRK) lacks Johnson & Johnson’s breadth and reliability track record. Johnson & Johnson’s diversified portfolio of medicines, medical devices, and consume ...

Here's Why You Don't Bet Against This Dividend King - 24/7 Wall St. S&P 5006,437.70 +1.39% Dow Jones45,713.20 +0.99% Nasdaq 10023,324.80 +1.61% Russell 20002,453.53 +1.64% FTSE 10010,172.40 +0.90% Nikkei 22551,667.30 +1.25% Stock Market Live March 31, 2026: S&P 500 (SPY) Pops on News Trump Could End War Investing Here's Why You Don't Bet Against This Dividend King By Rich DupreyPublished Mar 31, 11:30AM EDT Quick Read Johnson & Johnson (JNJ) raised its quarterly dividend from $1.24 to $1.30 per share (5% ...

Market Sentiment - The CNN Fear & Greed Index is at 13, indicating Extreme Fear, a significant drop from 8, the lowest level since 2022, when the collapse of Terraform Labs led to a $440 billion loss in market capitalization within a week [2][5] - The S&P 500 has declined by 7% year-to-date, while the Nasdaq-100 has entered correction territory due to its higher tech exposure [3] Investment Opportunities - Despite the overall market panic, high-quality companies like Apple, Microsoft, and Johnson & Johnson are trading at attractive valuations, with Apple reporting a revenue of $143.8 billion, a 16% year-over-year increase, and a diluted EPS of $2.84, up 19% [6][7] - Microsoft has a forward P/E ratio of 22.26x, while Johnson & Johnson offers a yield of 2.14%, indicating potential value for investors looking to deploy capital in quality names during this period of extreme fear [7] Market Behavior - The current sell-off has affected even the strongest companies with solid balance sheets and growing cash flows, surprising many retail investors [6] - The extreme fear level has only been observed on about 3.4% of trading days since 2011, suggesting a historically opportune moment for investors to consider quality investments rather than panic-selling [5][7]

Extreme Fear is Gripping the Market, This Is the Smart Move Most Investors Miss - 24/7 Wall St. Quick Read S&P 5006,416.40 +1.06% Dow Jones45,734.20 +1.04% Nasdaq 10023,210.80 +1.11% Russell 20002,446.83 +1.36% FTSE 10010,222.70 +1.40% Nikkei 22551,627.30 +1.18% Investing Extreme Fear is Gripping the Market, This Is the Smart Move Most Investors Miss By Rich DupreyPublished Mar 31, 8:09AM EDT Apple (AAPL), Microsoft (MSFT), and Johnson & Johnson (JNJ) are trading at attractive valuations despite posting ...